Wei-Ting Hwang, Ph.D.
Professor of Biostatistics in Biostatistics and Epidemiology at the Hospital of the University of Pennsylvania
Member, Biomedical Graduate Studies (BGS), University of Pennsylvania Perelman School of Medicine
Member, Clinical Trials Scientific Review and Monitoring Committee (CTSRMC), University of Pennsylvania Abramson Cancer Center
Senior Scholar, Center for Clinical Epidemiology and Biostatistics (CCEB), University of Pennsylvania Perelman School of Medicine
Associate Member, Abramson Cancer Center (ACC), University of Pennsylvania
Associate Fellow, Center for Health Behavior Research (CHBR), University of Pennsylvania Perelman School of Medicine
Associate Fellow, Center for Public Health Initiatives (CPHI), University of Pennsylvania Perelman School of Medicine
Director, Biostatistics, Bioinformatics, and Data Management Core. Extending Chimeric Antigen (CAR) T cell therapy to thoracic cancers
Faculty, Translational Research T32 Training Program in Environmental Health Sciences, University of Pennsylvania Perelman School of Medicine
Associate Director, Center of Excellence in Environmental Toxicology (CEET) Integrative Health Sciences Facility Core (IHSFC) Biostatistics Group
Member, Research Core Facilities Committee, University of Pennsylvania Perelman School of Medicine
Department: Biostatistics and Epidemiology
Graduate Group Affiliations
Contact information
Department of Biostatistics, Epidemiology and Informatics (DBEI)
Center for Clinical Epidemiology and Biostatistics (CCEB)
University of Pennsylvania Perelman School of Medicine
610 Blockley Hall
423 Guardian Drive
Philadelphia, PA 19104
Center for Clinical Epidemiology and Biostatistics (CCEB)
University of Pennsylvania Perelman School of Medicine
610 Blockley Hall
423 Guardian Drive
Philadelphia, PA 19104
Office: 215-573-5946
Fax: 215-573-4865
Fax: 215-573-4865
Publications
Education:
B.S. (Mathematics)
National Tsing-Hua University, Taiwan, 1995.
Ph.D. (Biostatistics)
Johns Hopkins University, School of Hygiene and Public Health, 2001.
Permanent linkB.S. (Mathematics)
National Tsing-Hua University, Taiwan, 1995.
Ph.D. (Biostatistics)
Johns Hopkins University, School of Hygiene and Public Health, 2001.
Description of Research Expertise
Biostatistics, survival data analysis, longitudinal studies, clinical trials, translational cancer research, biomarker discovery and validation, environmental health sciences, instrument development for psychosocial researchSelected Publications
Thompson JC*, Hwang W-T*, Davis C, Deshpande C, Jeffries S, Rajpurohit Y, Krishna V, Smirnov D, Verona R, Lorenzi MV, Langer CJ, Albelda SM. : Gene signatures of tumor inflammation and epithelial-to-mesenchymal transition (EMT) predict responses to immune checkpoint blockade in lung cancer with high accuracy. Lung Cancer 139: 1-8, Jan 2020 Notes: doi: 10.1016/j.lungcan.2019.10.012 * Equal contribution.Stadtmauer EA, Fraietta JA, Davis MM, Cohen AD, Weber KL, Lancaster E, Mangan PA, Kulikovskaya I, Gupta M, Chen F, Tian L, Gonzalez VE, Xu J, Jung IY, Melenhorst JJ, Plesa G, Shea J, Matlawski T, Cervini A, Gaymon AL, Desjardins S, Lamontagne A, Salas-Mckee J, Fesnak A, Siegel DL, Levine BL, Jadlowsky JK, Young RM, Chew A, Hwang W-T, Hexner EO, Carreno BM, Nobles CL, Bushman FD, Parker KR, Qi Y, Satpathy AT, Chang HY, Zhao Y, Lacey SF, June CH: CRISPR-engineered T cells in patients with refractory cancer. Science 367(eaba7365), Feb 2020 Notes: doi: 10.1126/science.aba7365 *: Lead statistician.
Zhu Y, Hwang W-T, Li Y: Evaluating the effects of design parameters on the performances of phase I trial designs. Contemporary Clinical Trials Communications(15), 100379, May 2019 Notes: doi: 10.1016/j.conctc.2019.100379.
Smith AM, Christodouleas JP, Hwang W-T*: Understanding the predictive value of continuous markers for censored survival data using a likelihood ratio approach BMC Medical Research Methodology 19(1): 108, May 2019 Notes: * senior author.
Joseph A. Fraietta JA*, Lacey SF*, Orlando EJ*, Ambrose DE, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Frey NV, Hwang W-T**, Parakandi H, Gupta M, Huang A, Johnson B, Kulikovskaya I, Levine BL, Liu L, Lundh SM, Pequignot R, Siegel DL, Wang V, Wherry EJ, Xu J, Young RM, Brogdon JL, Bitter H3, Porter DL, June CJ, Melenhorst JJ : Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine 24(5): 563-571, May 2018 Notes: *: Equal contribution, **: Statistical lead.
Yu D, Hwang W-T: Optimal cutoffs for continuous biomarkers for survival data under competing risks. Communications in Statistics - Simulation and Computation Page: 1-16, Jan 2018 Notes: *: Senior author. doi:10.1080/03610918.2017.1410713.
Xu R, Mesaros C, Weng L, Snyder NW, Vachani A, Blair IA, Hwang W-T*: Comparison of statistical methods for detection of serum lipid biomarkers for mesothelioma and asbestos exposure. Biomarkers in Medicine 11(7): 547-556, Jul 2017 Notes: *Senior author. The work and funding for the first author (Xu) is supported by Penn Superfund Research Center Biostatistics Core.
Garfall AL*, Maus MV*, Hwang W-T**, Lacey SF, Mahnke YD, Melenhorst JJ, Zheng Z, Vogl DT, Cohen AD, Weiss BM, Dengel K, Kerr ND, Bagg A, Levine BL, June CH, Stadtmauer EA: Chimeric antigen receptor T cells against CD19 for multiple myeloma. New England Journal of Medicine. *: Equal Contribution, 373(11): 1040-7, Sep 2015 Notes: ** Second/statistical author (276 citations to date).
Porter DL, Hwang W-T, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose D, Grupp SA, Chew A, Zheng Z, Milone M, Levine BL, Melenhorst JJ, June CH: Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine 7(303): 303ra139, Sep 2015 Notes: *: Second/statistical lead author (513 citations to date).
Rogers AE, Hwang W-T, Scott LD, Aiken LH, Dinges DF: The working hours of hospital staff nurses and patient safety. Health Affairs 23(4): 202-212, Jul-Aug 2004 Notes: (1044 citations up to date).
Harris EE, Correa C, Hwang W-T, Liao J, Litt HI, Ferrari VA, Solin LJ: Late cardiac mortality and morbidity in early-stage breast cancer patients after breast conservation treatment. Journal of Clinical Oncology 24(25): 4100-4106, Sep 2006 Notes: (333 citations up to date).
Scholler J, Brady TL, Binder-Scholl G, Hwang W-T, Plesa G, Hege KM, Vogel AN, Kalos M, Riley JL, Deeks SG, Mitsuyasu RT, Bernstein WB, Aronson NE, Levine BL, Bushman FD, June CH: Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Science Translational Medicine 4(132): 132ra53, May 2012 Notes: *Statistical lead (384 citations to date).
Tebas P, Stein D, Tang WW, Frank I, Wang SQ, Lee G, Spratt SK, Surosky RT, Giedlin MA, Nichol G, Holmes MC, Gregory PD, Ando DG, Kalos M, Collman RG, Binder-Scholl G, Plesa G, Hwang W-T, Levine BL, June CH: Gene editing of CCR5 in autologous CD4T cells of persons infected with HIV. New England Journal of Medicine 370(10): 901-10, Mar 2014 Notes: * Statistical lead for this first-in-man genome editing clinical trial (914 citations to date, 2015 Clinical Research Award).
Zhong Q, Peng HL, Zhao X, Zhang L*, Hwang W-T*: Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis. Clinical Cancer Research. *Senior authors, 21(1): 211-20, Jan 2015 Notes: The study was conducted according to PRISMA and MOOSE guidelines (77 citations to date).